Codix Group, a subsidiary of Colexa Biosensor Ltd, has been granted approval by the World Health Organization to manufacture and package a WHO Prequalified Rapid Diagnostic Test kit at its facility in Nigeria.
Colexa Biosensor is now able to package the WHO Prequalified HIV Rapid Diagnostic Test domestically thanks to the approval.
A statement by Codix Group on Wednesday said the milestone positions Nigeria as a key player in advancing healthcare production capabilities and improving access to life-saving diagnostics.
It read, “The Standard Q HIV 1/2 Ab 3-Line Test is now the first WHO Prequalified HIV RDT approved for packaging within Africa, marking a historic feat for the continent.”
The statement added that the accomplishment reflected the company’s dedication to strengthening Nigeria’s healthcare infrastructure and aligning with the President’s vision to enhance local manufacturing and innovation.
“Since its commissioning in December 2023, Colexa Biosensor has earned recognition from global health organizations, including WHO, Global Fund, UNITAID, FIND, and PEPFAR. The factory’s operational capacity represents a significant step toward reducing dependence on imports, improving access to high-quality In-Vitro Diagnostics (IVDs), and fostering Nigeria’s healthcare value chain.
“This approval also paves the way for procurement opportunities by Nigeria and international donors, further boosting local and global efforts to combat HIV. Codix Group expressed its pride in achieving this milestone and reaffirmed its commitment to elevating healthcare standards across the nation and beyond.”
According to the statement, the accomplishment is anticipated to spur additional funding for regional healthcare production, indicating a more promising future for the sector in Africa.
